Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center
Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.
Subcutaneous Toripalimab Meets Primary End Points in Nonsquamous NSCLC
The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line nonsquamous NSCLC.
The Paradigm of AML Care: What’s New and What’s Changing
According to Daniel Peters, MD, the recent FDA approvals of revumenib and ziftomenib in AML are some of the most exciting developments in the field.
Why Is Burden of Care the Biggest Challenge of Cancer Treatment?
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?
According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.
HRQOL Finds Similar Responses Between Surgery/Treatment Options in NMIBC
HRQOL scores were similar among patients who received a radical cystectomy or bladder persevering therapy for non-muscle invasive bladder cancer.
HR 2541: How May Its Implementation Impact Radiation Oncology Practice?
Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.
Handling the Burden of Financial Toxicity While Undergoing Cancer Therapy
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
How to Address Racial and Social Disparities in Pancreatic Cancer Care?
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?
A recent study found that the number of practicing oncologists is declining as the US population ages and cancer diagnoses continue to increase.
PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy
Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.
Early Detection, Education Are Key to Combat Rising Pancreatic Cancer Cases
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Examining Developments in Safe Administration of Nuclear Agents
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL
ORR, DOR, PFS, and OS showed continued improvement for patients with relapsed/refractory LBCL receiving tisagenlecleucel.
Sonrotoclax Earns FDA Priority Review in R/R Mantle Cell Lymphoma
The regulatory decision was supported by findings from the phase 1/2 BGB-11417-201 trial, which evaluated sonrotoclax monotherapy in those with MCL.
What Are the Barriers to Receiving Effective Breast Cancer Care?
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
177Lu/SBRT Improves PFS in Oligorecurrent Hormone-Sensitive Prostate Cancer
In the 177Lu plus SBRT arm, the median PFS was 17.6 months vs 7.4 months in the SBRT alone arm for patients with oligorecurrent HSPC.
Does Increased Infiltration Reporting Correlate with Better Outcomes?
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Novel Bispecific ADC Earns FDA Fast Track Status in Urothelial Cancer
Investigators are currently assessing the safety and preliminary activity of AVZO-103 among patients with advanced solid tumors in a phase 1/2 trial.
FDA Approves Durvalumab Plus FLOT in Resectable Gastric/GEJ Cancers
Results from MATTERHORN showed durvalumab plus FLOT improved EFS and OS compared with placebo plus FLOT in patients with gastric/GEJ cancers.
EU Approves Liso-Cel in R/R MCL With ≥ 2 Prior Lines of Systemic Therapy
Results from the TRANSCEND NHL 001 trial showed that liso-cel achieved an ORR of 82.7% in patients with previously treated mantle cell lymphoma.
Temferon Yields Preliminary Survival in Newly Diagnosed Glioblastoma Trial
One patient with newly diagnosed glioblastoma multiforme reached 3 years of survival following treatment with temferon in a phase 1/2a trial.
Cohort 7 of Novel MEK Inhibitor Trial Completed for MAPK Pathway-Driven Tumors
PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.
How Does Decision-Making Capacity, Patient-Centered Care Inform Oncology Decisions?
When a patient may not have the capability of understanding or consenting to treatment options, Louis P. Voigt, MD; and Yesne Alici, MD, will utilize decision-making capacity techniques.
Improving Prognoses in Patients With Brain Tumors or Hereditary Cancers
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
What’s New in Brain and Hereditary Cancers? Henson on Updates, Areas of Improvement
According to John Henson, MD, patients with ovarian, breast, endometrial, and colon cancers benefit the most from proactive hereditary analyses.
Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence
Researchers have observed that HSC–derived innate lymphoid cells prevent GVHD by inducing interleukin 9 driven T-cell senescence.
Tandem CAR T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time
Researchers have demonstrated that a tandem CAR T cell targeting mesothelin and MUC16 ectodomain is able to outmaneuver tumor heterogeneity, outperforming single target CAR T cells in mixed ovarian and pancreatic models.
Immune Priming Strategies Numerically Improve PFS in Ovarian Cancer
Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.
Non-Viral Gene Therapy Displays Feasibility in EGFR-Mutated NSCLC
No dose-limiting toxicities were observed among 12 patients with advanced EGFR-mutated NSCLC treated with quaratusugene ozeplasmid and osimertinib.
![According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fe0d29c38bb732429ae370e4ef7d1829a10c96446-2992x1684.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”")
